A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.
- Investigator
- Sonal S Tuli
- Ages
- 18 Years - N/A
- Sexes
- All
Clinical trials
-
KOWA 301 -
REC A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.
- Investigator
- Sonal S Tuli
- Ages
- 18 Years - N/A
- Sexes
- All
-
KOWA 303 A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
- Investigator
- Sonal S Tuli
- Ages
- 18 Years - N/A
- Sexes
- All
-
NRG-BR009: Testing the addition of chemo to SOC in breast cancer patients at high risk of recurrence This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal,…
- Investigator
- Karen Daily
- Ages
- 18 Years - 60 Years
- Sexes
- Female
-
UCB SL0043 The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
- Investigator
- Michael R Bubb
- Ages
- 16 Years - N/A
- Sexes
- All
-
BOSTON 3 The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
- Investigator
- Amir M Emtiazjoo
- Ages
- 18 Years - N/A
- Sexes
- All
-
RECOVER VITAL This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This…
- Ages
- 18 Years - N/A
- Sexes
- All
-
RECOVER-NEURO This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Ages
- 18 Years - N/A
- Sexes
- All